Stories
Hospital Stock Sell-Off: Buy Opportunity or Regulatory Risk? Analysts Divided
C
CNBC TV18•01-10-2026, 09:49
Hospital Stock Sell-Off: Buy Opportunity or Regulatory Risk? Analysts Divided
- •Indian hospital stocks, including Apollo Hospitals and Max Healthcare, plunged up to 7% after the Supreme Court questioned drug price markups.
- •The Supreme Court flagged a 10x markup on drug prices in hospitals and concerns over essential drugs being outside price control.
- •Jefferies views the sell-off as a buying opportunity, citing intact sector fundamentals despite potential 2-5% EBITDA impact from price caps.
- •HSBC acknowledges pricing control as a key market concern but notes current discussions focus on drug pricing in government channels.
- •The Supreme Court expressed concerns about hospitals forcing patients to buy drugs from in-house pharmacies; next hearing is October 12.
Key Questions Answered
Hospital stocks declined following Supreme Court observations regarding drug pricing margins, questioning why drugs billed to patients cost significantly more than what retailers pay and noting that essential drugs and devices fall outside price control orders.
Jefferies views the recent market correction as an attractive entry point for long-term investors, noting that the potential EBITDA impact from pricing caps on consumables and oncology drugs is expected to remain between 2% to 5% with sector fundamentals staying intact.
Regulatory fears primarily focus on consumables and oncology drug pricing, which are estimated to contribute between 15% and 20% of hospital revenues.
